QualityDipStocks / Health Care · Pharmaceuticals
Pfizer PFE
Outside our quality screen, so we don’t track its dips. It’s at its 52-week high.
Outside our quality screen, trading near our fair value estimate, 9% over its Market Value.
- Fair value est.
- $30.54at the price
- Market Value
- $28.07price +9%
- Off 52-wk high
- at the high
- Risk vs market
- Lowbeta 0.21
4 bullish · 5 bearish See why
Key levels
Every level vs today’s $30.52
- 52-wk lowlowest close, 1 year$23.67−22.4%
- Market Valueavg paid since Aug 4$28.07−8.0%
- PriceFri Oct 30 close$30.52you are here
- 52-wk highhighest close, 1 year$30.52at the price
- Fair value est.base case$30.54+0.1%
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 3.0% ±2 points. Bear = 10.5% and 1.0%; bull = 8.5% and 5.0% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price sits inside the range.
What the price implies To be worth today’s price, PFE’s free cash flow would need to grow about 3% a year for five years; our estimate uses 3%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much PFE moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Has moved mostly independently of the market, but its own price swings are 1.7× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.21
- Volatility
- 22% vs 13% SPY
- Correlation SPY
- 0.12
- Correlation QQQ
- −0.03
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
ProfitabilityGross margin widened to 74.3% in FY2025 from 58.1% in FY2023 (SEC filings).
Cash returnsDividend yield of 5.6% ($9.8B paid over 12 months).
ValuationFree-cash-flow yield of 6.3% (price / FCF 15.8×): $11.0B of free cash in the last 12 months.
ValuationPrice / book of 2.0×, below the 5.2× median for the 93 Health Care companies we cover.
Top bearish points 5 of 5
GrowthSales shrank 15% a year from FY2022 to FY2025.
Cash returnsPays out more in dividends than it earns: $9.8B paid vs $4.3B of net income.
ProfitabilityReturn on equity is only 5% over the last 12 months.
QualityDoesn’t pass our quality screen: ROE under 12% and ROIC under 10%; net debt 4.6× EBITDA (limit 3×).
ValuationTrades 8.7% above its Market Value of $28.07, the average price paid since the Aug 4 filing.
Who’s talking about it
Notable investors, executives, analysts and public figures on Pfizer in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
All fundamentals
P/E 40.1 · FCF yield 6.3% · ROE 5%
Valuation
- P/E
- 40.1×Health Care median 29.2×
- Price / FCF
- 15.8×
- FCF yield
- 6.3%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 2.73×
- Price / book
- 2.04×
- Market cap
- $174Bprice × diluted shares
- Enterprise value
- $229B
Growth
- Revenue, 12 months
- $63.7B
- Sales growth, 12 months
- −0.2%vs the 12 months before
- Sales growth, 3 yrs
- −14.8%/yrfrom FY2022
- Diluted EPS, 12 months
- $0.76
- EPS growth, last FY
- −3.5%
- Net income, 12 months
- $4.3B
- Net income growth
- −60%12 months vs before
Profitability
- Gross margin
- 73.2%
- Operating margin
- n/anot reported in its SEC filings
- Net margin
- 6.8%
- FCF margin
- 17.2%
- Return on equity
- 5%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $8.3B
- Total debt
- $63.1B
- Net cash
- −$54.8B
- Debt / equity
- 0.74×
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- $11.0B
- FCF growth, 12 months
- −12%
- Dividend yield
- 5.63%$9.8B paid
- Payout ratio
- 226%
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- −0.1%diluted shares vs a year ago
- Stock-based comp
- $947M
Trailing 12 months to Jun 28, 2026; balance sheet at Jun 28, 2026. From Pfizer’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
DCF $30.54 · MV $28.07 · FCF value $49.08
Assumes 3.0% growth for 5 years (revenue grew -14.8% a year FY22–FY25; floored at 3%), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $1.93 a share (trailing 12 months to Jun 28, 2026), from the 10-Q filed Aug 4, 2026. Net debt $54.8B, not deducted.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Momentum & 52-week range
RSI 66 · 5 days +1.6%
The business
FCF $11.0B · Sales +3%
- Free cash flow, 12 months$11.0B
- Free-cash-flow yield6.4%
- Free-cash-flow margin17%
- Gross margin73%
- Operating margin27%
- Return on invested capital9%
- Return on equity5%
- Sales growth (latest quarter vs year-ago quarter)+3%
- Net debt / EBITDA4.6×
Next report
Nov 3
- DateTue Nov 3, before the open
- Consensus EPS$0.72
- Year-ago EPS$0.87
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
PFE is outside our quality screen
One text when a published rule fires on one of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.